Alluvi, formerly BI 4744, presents a notable breakthrough in obesity therapy. This dual agonist targeting both GLP-1 and GIP sites demonstrates remarkable effectiveness in patient assessments, arguably outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/